An 18-Gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mannelqvist, Monica ^a   Wik, Elisabeth ^a,b   Stefansson, Ingunn M ^a,b   Akslen, Lars A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; DISEASE SPECIFIC SURVIVAL; GENE EXPRESSION; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TUMOR GROWTH; TUMOR INVASION; VASCULAR INVASION; BIOLOGY; BLOOD VESSEL; BREAST NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; LYMPH VESSEL; PATHOLOGY; TREATMENT OUTCOME; TUMOR GENE; VASCULARIZATION;

BLOOD VESSELS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; LYMPHATIC VESSELS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902603056     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098787     Document Type: Article

References (27)

1. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA (2009) Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology 54: 174-183.
2. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, et al. (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24: 41-47. (Pubitemid 24223138)
3. Straume O, Akslen LA (1996) Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78: 1211-1219. (Pubitemid 26303886)
4. Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, et al. (2000) Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126: 309-312. (Pubitemid 30140383)
5. Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bo T, Oyan AM, et al. (2011) Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 178: 861-871.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. (Pubitemid 32878711)
7. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
8. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, et al. (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16: 5351-5361.
9. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, et al. (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12: R5.
10. Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 108: 191-201. (Pubitemid 351311362)
11. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, et al. (2008) Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 3: e1373.
12. Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143.
13. de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, et al. (2011) Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer 11: 215.
14. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, et al. (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305: 1873-1881.
15. Gluck S, Ross JS, Royce M, McKenna EF, Jr., Perou CM, et al. (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab. Breast Cancer Res Treat.
16. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28: 4111-4119.
17. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, et al. (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116: 303-309.
18. Hu Z, Fan C, Livasy C, He X, Oh DS, et al. (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7: 9.
19. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7.
20. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, et al. (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8: 41.
21. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
22. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521. (Pubitemid 40814659)
23. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
24. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826. (Pubitemid 40051905)
25. Kadivar M, Mafi N, Joulaee A, Shamshiri A, Hosseini N (2012) Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011. Asian Pac J Cancer Prev 13: 1881-1886.
26. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11: 55-65.
27. Borgan E, Lindholm EM, Moestue S, Maelandsmo GM, Lingjaerde OC, et al. (2013) Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol 7: 130-142.